[1]秦焕蓉,吴祥锴,江哲宇,等.微小核糖核酸-155对肝癌细胞增殖、侵袭迁移和凋亡的影响[J].介入放射学杂志,2024,33(01):44-51.
 QIN Huanrong,WU Xiangkai,JIANG Zheyu,et al.The effect of microRNA-155 on the proliferation, invasion, migration and apoptosis of hepatocellular carcinoma cells[J].journal interventional radiology,2024,33(01):44-51.
点击复制

微小核糖核酸-155对肝癌细胞增殖、侵袭迁移和凋亡的影响()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年01
页码:
44-51
栏目:
实验研究
出版日期:
2024-01-31

文章信息/Info

Title:
The effect of microRNA-155 on the proliferation, invasion, migration and apoptosis of hepatocellular carcinoma cells
作者:
秦焕蓉 吴祥锴 江哲宇 张 赟 林丽云 王黎洲 周 石
Author(s):
QIN Huanrong WU Xiangkai JIANG Zheyu ZHANG Yun LIN Liyun WANG Lizhou ZHOU Shi.
School of Medical Imaging, Guizhou Medical University, Guiyang, Guizhou Province 550004, China
关键词:
【关键词】 肝癌微小核糖核酸-155蛋白酪氨酸磷酸酶非受体21型磷脂酰肌醇3-激酶蛋白激酶B
文献标志码:
A
摘要:
【摘要】 目的 探究微小核糖核酸(miR)- 155靶向蛋白酪氨酸磷酸酶非受体21型(PTPN21)调控磷脂酰肌醇3- 激酶(PI3K)/蛋白激酶B(AKT)信号通路对肝癌细胞增殖、迁移、侵袭的影响。方法 体外培养Huh7人肝癌细胞并通过miR- 155沉默慢病毒(sh- miR- 155)转染下调miR- 155。实时荧光定量聚合酶链反应(RT- qPCR)检测Huh7细胞miR- 155沉默效果,获得稳转细胞株后将细胞株随机分为:Blank组(正常Huh7细胞)、shNC组(Huh7细胞+miR- 155空载体)、sh- miR- 155组(Huh7细胞+miR- 155沉默)、sh- miR- 155+Recilisib组(Huh7细胞+miR- 155沉默+PI3K- AKT激动剂)、shNC+Recilisib组(Huh7细胞+miR- 155空载体+PI3K- AKT激动剂)。双荧光素酶实验检测PTPN21 是否为miR- 155的下游;溴化噻唑蓝四氮唑(MTT)法检测各组细胞增殖能力;流式细胞术测定各组细胞凋亡水平;Transwell实验分析各组细胞侵袭与迁移能力;蛋白质印迹检测各组PTPN21、通路相关蛋白PI3K、P- PI3K、AKT、P- AKT及凋亡相关蛋白BAX、BCL- 2、Caspase- 3表达变化差异。结果 sh- miR- 155组中miR- 155的表达水平低于Blank组及shNC组(P<0.000 1), miR- 155在Blank组及shNC组表达水平差异无统计学意义(P>0.05)。MTT结果显示,sh- miR- 155组中Huh7细胞在2、3、4、5 d时A值均低于Blank组及shNC组(P<0.000 1),而Blank组与shNC组差异无统计学意义(P>0.05);sh- miR- 155组在2、3、4、5 d时A值低于sh- miR- 155+Recilisib组及shNC+Recilisib组(P=0.005 2, P<0.000 1),而sh- miR- 155+Recilisib组在2、3、4、5 d时A值低于shNC+Recilisib组(P<0.000 1)。Blank组与shNC组迁移及侵袭细胞数差异无统计学意义(P>0.05),激活PI3K- AKT信号通路后,与Blank组相比,shNC+Recilisib组肝癌细胞的迁移、侵袭能力显著增加(P<0.000 1)。相反,沉默miR- 155后Huh7细胞的迁移及侵袭细胞数明显低于Blank组及shNC组(P<0.000 1),而PI3K激动剂逆转了这一现象,与sh- miR- 155组相比,sh- miR- 155+Recilisib组肝癌细胞的迁移、侵袭能力增强(P=0.000 2)。慢病毒转染Huh7人肝癌细胞以沉默miR- 155,下调miR- 155抑制PTPN21调控PI3K- AKT信号通路从而抑制肝癌细胞的侵袭、迁移、增殖能力,促进肝癌细胞凋亡。结论 miR- 155通过靶向PTPN21调控PI3K- AKT信号通路抑制肝癌细胞的迁移、侵袭、增殖。miR- 155可能是未来肝癌治疗潜在靶点。

参考文献/References:

[1] Zucman- Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149: 1226- 1239.
[2] 杨 鹏,何 洋,李 成,等. 微小核糖核酸- 7调控表皮细胞生长因子受体对肝癌细胞增殖和转移的影响[J]. 介入放射学杂志, 2021, 30:43- 47.
[3] Liu J, Fan L, Yu H, et al. Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR- 23a- 3p and up- regulate programmed death ligand 1 expression in macrophages[J]. Hepatology, 2019, 70: 241- 258.
[4] Santos DAR, Gaiteiro C, Santos M, et al. MicroRNA biomarkers as promising tools for early colorectal cancer screening: a comprehensive review[J]. Int J Mol Sci, 2023, 24: 11023.
[5] Chen S, Wang Y, Li D, et al. Mechanisms controlling microRNA expression in tumor[J]. Cells, 2022, 11: 2852.
[6] Wang J, Wang Q, Guan Y, et al. Breast cancer cell- derived microRNA- 155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function[J]. J Clin Invest, 2022, 132: e157248.
[7] Fang H, Shuang D, Yi Z, et al. Up- regulated microRNA- 155 expression is associated with poor prognosis in cervical cancer patients[J]. Biomed Pharmacother, 2016, 83: 64- 69.
[8] Fu X, Wen H, Jing L, et al. MicroRNA- 155- 5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway[J]. Cancer Sci, 2017, 108: 620- 631.
[9] 王 奕,韩 涛,张志强,等. 血清微小核糖核酸- 599与肝细胞肝癌TACE治疗预后的相关性[J]. 介入放射学杂志, 2021,30:1265- 1270.
[10] Zhang Y, Li X, Zhang Y, et al. Pegylated interferon- α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR- 155[J]. Ann Hepatol, 2019, 18: 494- 500.
[11] Eldosoky MA, Hammad R, Elmadbouly AA, et al. Diagnostic significance of hsa- miR- 21- 5p, hsa- miR- 192- 5p, hsa- miR- 155- 5p, hsa- miR- 199a- 5p panel and ratios in hepatocellular carcinoma on top of liver cirrhosis in HCV- infected patients[J]. Int J Mol Sci, 2023, 24: 3157.
[12] Basova P, Pesta M, Sochor M, et al. Prediction potential of serum miR- 155 and miR- 24 for relapsing early breast cancer[J]. Int J Mol Sci, 2017, 18: 2116.
[13] Guan C, Yang F, He X, et al. Clinical significance of microRNA- 155 expression in hepatocellular carcinoma[J]. Oncol Lett, 2016, 11: 1574- 1580.
[14] Wang CC, Shen WJ, Anuraga G, et al. Novel potential therapeutic targets of PTPN families for lung cancer[J]. J Pers Med, 2022, 12: 1947.
[15] Carlucci A, Porpora M, Garbi C, et al. PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells[J]. J Biol Chem, 2010, 285: 39260- 39270.
[16] Plani- Lam JH, Chow TC, Fan YH, et al. High expression of PTPN21 in B- cell non- Hodgkin’s gastric lymphoma, a positive mediator of STAT5 activity[J]. Blood Cancer J, 2016, 6: e388.
[17] Han W, Wang N, Kong R, et al. Ligand- activated PPARδ expression promotes hepatocellular carcinoma progression by regulating the PI3K- AKT signaling pathway[J]. J Transl Med, 2022, 20: 86.
[18] Ghafouri- Fard S, Abak A, Tondro Anamag F, et al. The emerging role of non- coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process[J]. Biomed Pharmacother, 2021, 137: 111279.
[19] Rahmani F, Ziaeemehr A, Shahidsales S, et al. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma[J]. J Cell Physiol, 2020, 235: 4146- 4152.
[20] 吴佳明, 邓忠权, 朱 奕, 等. MicroRNA- 431- 5p在胃癌组织中低表达:基于线粒体和Bax/Bcl- 2/caspase 3信号通路[J]. 南方医科大学学报, 2023, 43: 537- 543.
[21] Li XQ, Liu BC, Jiang XB, et al. Inhibition of PTPN21 has antitumor effects in glioma by restraining the EGFR/PI3K/AKT pathway[J]. Toxicol Appl Pharmacol, 2022, 451: 116180.

相似文献/References:

[1]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
 .The volume of Lipiodol used in TACE: its current situation and research progress [J].journal interventional radiology,2012,(01):348.
[2]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗30例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
 ,,et al.TACE combined with radiofrequency ablation for massive primary hepatocellular carcinomas: a clinical therapeutic evaluation [J].journal interventional radiology,2012,(01):322.
[3]张   磊,陆骊工,李   勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
 ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(01):968.
[4]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
 AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(01):1010.
[5]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
 DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(01):75.
[6]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
 ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(01):78.
[7]何海涛,刘 圣,刘建秦,等. 肝癌TACE术并发脑碘油栓塞二例并文献复习[J].介入放射学杂志,2012,(08):682.
 HE Hai- tao,LIU sheng,LIU Jian- qing,et al. Cerebral Lipiodol embolism occurred after transcatheter arterial chemoembolization for hepatocellular carcinoma: report of two cases with literature review[J].journal interventional radiology,2012,(01):682.
[8]罗中华,秦 勉,张学昕,等.原发性肝癌合并下腔静脉及右心房癌栓的动脉内化疗栓塞治疗[J].介入放射学杂志,2012,(12):1035.
 LUO Zhong? hua,QIN Mian,ZHANG Xue? xin,et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by tumor thrombus in inferior vena cava and right atrium[J].journal interventional radiology,2012,(01):1035.
[9]徐 阳,臧 爽,陈路锋,等.Logistic回归及ROC曲线综合评价血生化指标对肝癌TACE术后发热的预测价值 [J].介入放射学杂志,2013,(06):513.
 XU Yang,ZANG Shuang,CHEN Lu? feng,et al. Combination evaluation of plasma biochemical indexes with Logistic regression and ROC analysis in predicting hyperthermia after transcatheter hepatic arterial chemoembolization for liver cancer[J].journal interventional radiology,2013,(01):513.
[10]彭国文,李晓群. 射频消融及组合方案治疗特殊/高危部位肝癌的中远期疗效[J].介入放射学杂志,2013,(06):525.
 PENG Guo? wen,LI Xiao? qun.. The mid?蛳 to?蛳 long term efficacy of radiofrequency ablation together with combination regimen for the treatment of hepatic carcinomas located at special or high?蛳 risk regions[J].journal interventional radiology,2013,(01):525.

备注/Memo

备注/Memo:
 (收稿日期:2023- 07- 03)
(本文编辑:新 宇)
更新日期/Last Update: 2024-01-30